Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Sulfamonomethoxine: Workflow and Troubleshooting
2026-09-30
Sulfamonomethoxine (SMM) supports controlled antibacterial, aquaculture, toxicity, and biotransformation studies without treating environmental removal as proof of detoxification. This practical guide connects DHPS inhibition with solvent handling, aerobic granular sludge assays, EPS controls, and troubleshooting for reliable results.
-
Aging Lens Epithelium and Ferroptosis: RSL3 Insights
2026-09-29
Wei and colleagues show that aging lens epithelial cells become unusually vulnerable to ferroptosis, linking age-related cataract biology with defects in glutathione, iron, and lipid-redox homeostasis. Their combination of pharmacological perturbation, ex vivo lens models, and transcriptome analysis provides a framework for interpreting RSL3 responses beyond cancer-focused ferroptosis studies.
-
Protein A/G Magnetic Co-IP/IP Kit Guide
2026-09-29
A scenario-based guide to using the Protein A/G Magnetic Co-IP/IP Kit, SKU K1309, for reproducible protein-complex isolation alongside cell viability, proliferation, and cytotoxicity assays. It explains compatibility, optimization, controls, interpretation, and practical vendor-selection criteria for biomedical laboratories.
-
From Co-IP Signals to Bone-Formation Mechanisms
2026-09-28
A translational guide to using mechanistic Co-IP workflows to connect PML–HIF1AN association, ubiquitination, and PI3K/AKT signaling with osteogenic differentiation in bone marrow mesenchymal stem cells.
-
DiI (DiIC18(3)) Membrane Probe Workflow
2026-09-28
DiI (DiIC18(3)) provides orange-red plasma membrane labeling for live or fixed cells and tissues, supporting membrane imaging, neuronal tracing, and migration or adhesion studies. It is not water-soluble or an organelle-selective stain; use a compatible organic-solvent stock and validate membrane retention in the exact fixation and imaging workflow.
-
Rosiglitazone: From PPARγ Agonism to Rescue Biology
2026-09-27
Rosiglitazone (Brl-49653) offers researchers a way to probe PPARγ-dependent adipocyte programs—and to ask a more translational question: when PPARG function is impaired, can residual signaling still be engaged? We connect recent R212W functional findings to practical study design, assay controls, and the limits of interpreting agonist-mediated rescue.
-
BOP Reagent: Cell-Assay Workflow Boundaries
2026-09-26
Learn where BOP reagent (SKU A7015) fits—and where it does not—in cell viability, proliferation, and cytotoxicity workflows. This scenario-based guide covers its documented specifications, practical handling, and the distinction between peptide synthesis and cell-based assay performance.
-
MHI148 Photodynamic Therapy Plus STING Activation
2026-09-25
A multifunctional nanoparticle combining the photosensitizer MHI148 with the STING agonist 2′3′-cGAMP paired light-triggered tumor-cell killing with immune stimulation. The study reports enhanced dendritic-cell maturation, CD8+ T-cell infiltration, and antitumor effects, while highlighting delivery and model-specific questions that remain for translation.
-
EZ Cap™ Reagent AG: Evidence and BHD mRNA Limits
2026-09-25
EZ Cap™ Reagent AG is identified in the supplied product dossier as APExBIO SKU B8176, but the dossier provides no formulation or protocol specifications. A 2026 study reported that synthetic FLCN mRNA restored folliculin expression and corrected mTORC1 dysregulation in cultured cells; it does not establish that B8176 was used or that the product treats Birt-Hogg-Dubé syndrome.
-
Leptin (116-130), amide, mouse: Lab Workflow
2026-09-24
Use this amidated mouse leptin fragment to design focused metabolic and immunometabolic assays, with careful controls that distinguish fragment activity from full-length leptin biology. The workflow emphasizes fresh preparation, dose-finding, functional readouts, and the limits of borrowing experimental logic from a separate atrial-fibrillation study.
-
CpAdhE Inhibition Reveals a Cryptosporidium Drug Target
2026-09-24
A 2024 study characterized the fermentative enzyme CpAdhE in Cryptosporidium parvum and identified antifungal imidazoles and unsaturated fatty acids as inhibitors in a biochemical screen. Three imidazoles also reduced parasite growth in vitro, supporting further investigation while leaving target engagement, selectivity, and in vivo efficacy to be established.
-
SEMA3E Drives Beige Adipocyte Thermogenesis via β-Catenin
2026-09-23
A 2026 mouse study identifies SEMA3E as a regulator of beige adipocyte differentiation and thermogenesis, linking its effects to mitochondrial oxidative phosphorylation and β-catenin signaling. The combination of cell-based perturbations, adipose-tissue knockdown, and functional readouts supports a role for SEMA3E in cold- and agonist-induced thermogenic responses, while leaving important questions about pathway dynamics and applicability to humans.
-
Rosiglitazone (Brl-49653) Adipogenesis Workflows
2026-09-23
Build reproducible PPARγ activation experiments with Rosiglitazone (Brl-49653), from DMSO stock preparation to adipocyte differentiation, glucose-handling assays, and mitochondrial readouts. The workflow also shows how pharmacological PPARγ stimulation can complement SEMA3E gain- and loss-of-function studies without conflating adipogenesis with thermogenesis.
-
Protease Inhibitor Cocktail for Lipid Droplet Assays
2026-09-22
Protect DFCP1–ATGL interactions and other labile targets during cell and tissue extraction with a broad-spectrum, water-soluble inhibitor mixture. This practical guide covers 1X setup, EDTA-sensitive assays, Co-IP and kinase workflows, plus troubleshooting for lipid droplet research.
-
ABT-737 and Mitochondrial RNA During Apoptosis
2026-09-22
ABT-737 is a selective BCL-2 protein inhibitor for studying mitochondrial apoptosis in cancer models. This article connects its BAK-dependent mechanism with super-resolution imaging of mitochondrial mRNA, offering a practical framework for resolving apoptotic signaling from mitochondrial RNA remodeling.